NCT03345485 · OUTCOME
Summary of Half-life of Tinostamustine in Phase 2 and Substudies.
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. · Source last updated 2024-10-21
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- hour
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Blood samples were collected over a period of 24hr (phase 2 and sub-study 1) and 30hr (sub-study 2) on Cycle 1 Day 1 and Day 15.
Analysis population: All enrolled subjects in the Safety Population with at least 1 quantifiable pre-dose and 1 quantifiable post-dose PK plasma concentration in Cycle 1 were included in the PK Population. PK analyses were performed using the PK population. 48 subjects of the Safety Population were included in the PK Population.
Groups in this outcome
Tinostamustine (EDO-S101) - Sub Study 1 (SS1)
A dose of 60 mg/m2 administered over 60 minutes on D1 and D15 of 4-week cycles
Tinostamustine (EDO-S101) - Sub Study 2 (SS2)
A dose of 80 mg/m2 administered over 80 minutes on D1 and D15 of 4-week cycles.
Phase 2 All Cohorts
A dose of 80 mg/m2 administered over 60 minutes on D1 and D15 of 4-week cycles.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 6 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 7 |
|---|
| Phase 2 All Cohorts | 35 |
|---|
Reported measurements
EDO-S101 concentration, Cycle 1 D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 4 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 3 |
|---|
| Phase 2 All Cohorts | 28 |
|---|
Values in hour · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 0.919 | 38 | Not reported | Not reported | Not reported |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 2.14 | 185 | Not reported | Not reported | Not reported |
|---|
| Phase 2 All Cohorts | 0.70 | 54 | Not reported | Not reported | Not reported |
|---|
EDO-S101 concentration, Cycle 1 D15
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 3 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 2 |
|---|
| Phase 2 All Cohorts | 20 |
|---|
Values in hour · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 0.678 | 45.8 | Not reported | Not reported | Not reported |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 4.03 | 2150 | Not reported | Not reported | Not reported |
|---|
| Phase 2 All Cohorts | 0.704 | 51.2 | Not reported | Not reported | Not reported |
|---|
M2 metabolite concentration, Cycle 1 D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 6 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 7 |
|---|
| Phase 2 All Cohorts | 35 |
|---|
Values in hour · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | NA | NA | Not reported | Not reported | M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived. |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | NA | NA | Not reported | Not reported | M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived. |
|---|
| Phase 2 All Cohorts | NA | NA | Not reported | Not reported | M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived. |
|---|
M2 metabolite concentration, Cycle 1 D15
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 6 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 7 |
|---|
| Phase 2 All Cohorts | 35 |
|---|
Values in hour · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | NA | NA | Not reported | Not reported | M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived. |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | NA | NA | Not reported | Not reported | M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived. |
|---|
| Phase 2 All Cohorts | NA | NA | Not reported | Not reported | M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived. |
|---|
M8 metabolite concentration, Cycle 1 D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 3 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 7 |
|---|
| Phase 2 All Cohorts | 17 |
|---|
Values in hour · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 0.602 | 30.2 | Not reported | Not reported | Not reported |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 1.22 | 96.8 | Not reported | Not reported | Not reported |
|---|
| Phase 2 All Cohorts | 0.414 | 49 | Not reported | Not reported | Not reported |
|---|
M8 metabolite concentration, Cycle 1 D15
Analysis denominator · Participants
| Group | Source count |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 3 |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 7 |
|---|
| Phase 2 All Cohorts | 7 |
|---|
Values in hour · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Tinostamustine (EDO-S101) - Sub Study 1 (SS1) | 2.30 | 153 | Not reported | Not reported | Not reported |
|---|
| Tinostamustine (EDO-S101) - Sub Study 2 (SS2) | 2.48 | 99.7 | Not reported | Not reported | Not reported |
|---|
| Phase 2 All Cohorts | 4.43 | 553 | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 38
- value
- 0.919
- group Id
- OG001
- spread
- 185
- value
- 2.14
- group Id
- OG002
- spread
- 54
- value
- 0.70
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 28
- units
- Participants
- title
- EDO-S101 concentration, Cycle 1 D1
- categories
- measurements
- group Id
- OG000
- spread
- 45.8
- value
- 0.678
- group Id
- OG001
- spread
- 2150
- value
- 4.03
- group Id
- OG002
- spread
- 51.2
- value
- 0.704
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 20
- units
- Participants
- title
- EDO-S101 concentration, Cycle 1 D15
- categories
- measurements
- comment
- M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived.
- group Id
- OG000
- spread
- NA
- value
- NA
- comment
- M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived.
- group Id
- OG001
- spread
- NA
- value
- NA
- comment
- M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived.
- group Id
- OG002
- spread
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 35
- units
- Participants
- title
- M2 metabolite concentration, Cycle 1 D1
- categories
- measurements
- comment
- M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived.
- group Id
- OG000
- spread
- NA
- value
- NA
- comment
- M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived.
- group Id
- OG001
- spread
- NA
- value
- NA
- comment
- M2 metabolite plasma concentrations were either below the limit of quantification, or a regression line could not be fitted to calculate elimination rate constant due to R square value not meeting acceptance criteria. Therefore clearance could not be derived.
- group Id
- OG002
- spread
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 35
- units
- Participants
- title
- M2 metabolite concentration, Cycle 1 D15
- categories
- measurements
- group Id
- OG000
- spread
- 30.2
- value
- 0.602
- group Id
- OG001
- spread
- 96.8
- value
- 1.22
- group Id
- OG002
- spread
- 49
- value
- 0.414
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 17
- units
- Participants
- title
- M8 metabolite concentration, Cycle 1 D1
- categories
- measurements
- group Id
- OG000
- spread
- 153
- value
- 2.30
- group Id
- OG001
- spread
- 99.7
- value
- 2.48
- group Id
- OG002
- spread
- 553
- value
- 4.43
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 7
- units
- Participants
- title
- M8 metabolite concentration, Cycle 1 D15
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 35
- units
- Participants
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- A dose of 60 mg/m2 administered over 60 minutes on D1 and D15 of 4-week cycles
- id
- OG000
- title
- Tinostamustine (EDO-S101) - Sub Study 1 (SS1)
- description
- A dose of 80 mg/m2 administered over 80 minutes on D1 and D15 of 4-week cycles.
- id
- OG001
- title
- Tinostamustine (EDO-S101) - Sub Study 2 (SS2)
- description
- A dose of 80 mg/m2 administered over 60 minutes on D1 and D15 of 4-week cycles.
- id
- OG002
- title
- Phase 2 All Cohorts
- param Type
- GEOMETRIC_MEAN
- population Description
- All enrolled subjects in the Safety Population with at least 1 quantifiable pre-dose and 1 quantifiable post-dose PK plasma concentration in Cycle 1 were included in the PK Population. PK analyses were performed using the PK population. 48 subjects of the Safety Population were included in the PK Population.
- reporting Status
- POSTED
- time Frame
- Blood samples were collected over a period of 24hr (phase 2 and sub-study 1) and 30hr (sub-study 2) on Cycle 1 Day 1 and Day 15.
- title
- Summary of Half-life of Tinostamustine in Phase 2 and Substudies.
- type
- SECONDARY
- unit Of Measure
- hour
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle